The data support setmelanotide's efficacy but are unlikely to materially change near-term revenue. Monitor for regulatory updates in HO label expansion and upcoming quarterly earnings for prescription trends.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $91.31entry
- T+1 · 6mo ago +2.64%α +2.06% · $93.72
- T+5 · 6mo ago −4.90%α −4.97% · $86.84
- T+20 · 5mo ago −6.13%α −4.41% · $85.71
- T+60 · 3mo ago +22.77%α +18.38% · $112.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including significant BMI reductions (16.9% at 12 months) and improvements in cardiometabolic risk indices in acquired hypothalamic obesity. The data are encouraging but represent incremental conference presentations rather than a regulatory or financial catalyst.
Key Facts
- Real-world data showed 16.9% mean BMI reduction at 12 months in acquired HO (n=25, p<0.0001).
- Phase 3 TRANSCEND post hoc analysis: metabolic syndrome z-score improved -0.9 vs -0.2 placebo (p<0.0001).
- No new safety signals; adverse events consistent with prior Phase 3 trials.
- Six posters presented at ECE 2026; none represent regulatory filings or label expansions.
Financial Impact
No financial data provided; impact on revenue is indirect through potential future prescription uptake.
Risk Factors
- Clinical data may not translate to broad commercial adoption.
- Competition from other obesity therapies.
- Regulatory hurdles for label expansion remain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292752 |
Track record
26 reports on RYTM
9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers